Sentences with phrase «drug companies focused»

Not exact matches

Cannabis - focused drug company Zynerba can't seem to catch a break.

Instead of focusing on developing a blockbuster drug only to have it fail in trials, Tehrani's company would concentrate on the process of innovation.

One biotech firm, Ossianix, is already hard at work developing a VNAR - based drug - delivery system, in collaboration with the global pharmaceutical company Lundbeck, which focuses on drugs for brain disorders.

So in the case of CVS, Meyer and his team first made sure that the company's decision to rebrand was warranted: Leaders wanted to push its image as a more health - focused alternative to other drug stores.

One key differentiator is that these companies are testing with the Food and Drug Administration and making products for medical marijuana and MassRoots is focused on recreational marijuana users.

Prior to Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a clinical - stage biopharmaceutical company focused on the development of antibody - drug conjugates (ADCs) that was acquired by a consortium led by Fosun Pharmaceutical Group in 2015.

While Kallyope hasn't given too many specifics about its drug programs, the company's initial focus will be in metabolic conditions, like obesity, as well as neurologic conditions like Parkinson's disease.

The company has responded with statements saying that it's not as dependent on drug price increases as critics have claimed; it has also pointed out that while attention has focused on changes in list prices for drugs, those prices don't reflect the actual cost for insurers, governments and other group purchasers, which typically receive discounts that aren't publicly disclosed.

The memory - eating disease, expected to afflict 15 million Americans by 2060 (and tens of millions more around the world as life expectancy increases), has no cure; a new drug for the condition hasn't been approved in well over a decade; initially promising experimental treatments seem to be failing with clockwork regularity; and there's not even a definitive consensus on what, exactly, biopharma companies should focus on while developing Alzheimer's medicines.

As I've previously reported, Roivant and its federation of biopharma companies focused on developing drugs in specific disease spaces is attempting a very new form of pharmaceutical R&D.

Today, a lot of companies are focusing on drugs that can target specific and rare diseases.

Biotech giant Gilead Sciences is beefing up its cancer drug portfolio with a $ 11.9 billion deal to buy Kite Pharma, a company focused on a groundbreaking new class of treatments that turns the body's own immune cells into targeted blood cancer killers.

CalciMedica is a privately - held, clinical stage biopharmaceutical company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.

They've gone from a big, diversified drug company to a highly focused biopharma firm.»

Sierra Oncology, Inc., a clinical stage drug development company focused on advancing next - generation DNA damage response therapeutics for the treatment of patients with cancer, went public near $ 29 in July 2015, then began a downtrend that continued through a June 2017 all - time low of $ 1.10.

The company focuses on cancer drug research and has a platform for so - called «real - world» data, which can be used to assess the economic value of medicines and is sought after by drug makers looking to justify their prices to health insurers.

One area of focus may be Medicare; both companies are significant players in offering prescription drug plans to Medicare beneficiaries.

Andrew's primary responsibility at RA Capital is to evaluate public and private investments in companies developing drugs, medical devices, diagnostics, and research tools, with a focus on new company formation.

SOUTH SAN FRANCISCO, Calif. — February 5, 2018 — FLX Bio, Inc., a biopharmaceutical company focused on the discovery and development of oral small molecule drugs to activate the immune system against cancer, today announced the appointment of senior pharmaceutical research and development executive Michael F. Giordano, M.D., to its Board of Directors.

Represented European based biotech company, focused on drug delivery solutions, with respect to its inbound and outbound licensing transactions and those related to the development, manufacture and supply of key components of its technologies.

The company is led by its founder Leonard Schleifer who maintains a culture focused on developing novel drugs.

The divestment would complete the company's gradual shift away from its original focus on generic drugs and nuclear imaging toward branded specialty pharmaceuticals, which now comprise the bulk of its revenues.

The company said it would instead focus on educating doctors about the drug and the condition it treats, hypoactive sexual desire disorder.

The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment.

The company is led by its founder Len Schleifer who maintains a culture focused on internal development of novel new drugs.

DURECT Corp. is a biopharmaceutical company focused on two areas of active drug development: New therapeutics based on its proprietary drug delivery platforms and new chemical entities derived from its epigenomic regulator program.

Alkermes is a commercial - stage company that focuses on drugs for central nervous system disorders, and could have some major catalysts in 2018.

He has helped found at least two dozen biotech companies, with foci ranging from cancer drug delivery to products for hair and skin.

Opsona Therapeutics, for example, a drug development company focusing on the regulation of the human immune system, was founded in Dublin in 2004 by three immunologists at Trinity College Dublin.

The company that emerged on the other side was slimmer, shedding the weight of a large, too - diversified drug company to become a biopharmaceutical firm focused on specialty therapies for high medical needs.

The focus on innovation is just as important for other types of biotechnology companies, even ones that are not in the business of making drugs.

He adds, «This is developing as a path where you can have very focused, specialized university researchers and / or scientists from smaller companies interacting with larger companies to facilitate getting drugs developed.»

Her first post-postdoc job, in 1988, was at Seattle - based Immunex, then a 7 - year - old company focused on developing drugs to treat immune - system disorders.

A biotech company is a tightly focused environment, where freedom of academic inquiry is often curbed in the interest of completing a project as quickly as possible, whether it's a new drug, a diagnostic technique, or some other science - related product.

Developing broad - spectrum drugs for the battlefield has proved difficult because regulators are more accustomed to evaluating drugs that target one specific disease, and drug companies prefer to focus on diseases that affect many people rather than on obscure pathogens that could serve as bioweapons.

For decades, pharmaceutical companies have treated ß amyloid as a «freak» with no beneficial purpose, and focused nearly all their energies on finding drugs to eliminate the molecules, he says.

Focusing on patent litigation, I was involved in many of the battles between the innovators of a drug and the generic companies who wished to copy the drug.

But while LDDN focuses on the earliest stages of drug development — identifying compounds and confirming their biological activity — PharmaStart may take the process much further before signing on with a drug company.

Another pioneer in the field of EAPs is Micromuscle AB, a company based in Linköping, Sweden, that focuses on medical device applications in the areas of cardiovascular treatment and drug delivery.

His work focused on drug company payments to a psychiatrist at the University of Cincinnati, another at Stanford University, and Charles Nemeroff, then with Emory University — causing much chaos and agitation among researchers — and changes in numerous academic conflict - of - interest policies.

Pharmaceutical companies, by contrast, focus most of their efforts at the other end of the drug development pipeline, moving potential drug compounds through human clinical trials into the market.

The biggest UK employers in industry are Smith & Nephew, a research company focused on wound care, and drug company Pfizer, whose research includes developing stem cell therapies for Crohn's disease.

SOUTH PLAINFIELD, NJ — December 6, 2007 — PTC Therapeutics, Inc. (PTC), a biopharmaceutical company focused on the discovery, development, and commercialization of small - molecule drugs targeting post-transcriptional control mechanisms, today announced an expanded research collaboration with the Spinal Muscular Atrophy (SMA) Foundation.

Kancera AB is a biotechnology company that focuses on the development and sale of drug candidates that have the potential to cure or stop the progression of cancer.

In its inaugural collaboration that focuses on small molecule drug discovery, IACS has signed an exclusive agreement with TESARO, Inc., an oncology - focused biopharmaceutical company.

• Flowmetric — Founded by CEO, Ren Capocasale, Flowmetric is a contract research organization focused on providing polychromatic flow cytometry and cell sorting services to bio-pharma and drug discovery companies.

He served as Laboratory Director at biotech company, Prosetta Corporation, leading several small molecule drug discovery programs focused on viruses of interest to the United States Department of Defense.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small - molecule drugs that target post-transcriptional control processes.

PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small - molecule drugs that target post-transcriptional control processes.

About PTC Therapeutics PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes.